Mary Buchanan lived a tragedy. In 1996, soon after the Food and Drug Administration approved a new Wyeth prescription weight loss drug called Redux, she began taking it. Redux stayed on the market for less than two years; Wyeth pulled the drug in 1997, after it became clear that Redux users had a significantly elevated risk of developing primary pulmonary hypertension, a potentially fatal disorder. That was too late for Mary Buchanan. She was diagnosed with primary pulmonary hypertension in 2001 and died of it in 2003.

Her estate continued to pursue the product liability and negligence suit she had filed against Wyeth (now part of Pfizer). The case was a complete failure at the federal district court level. In 2008 Cleveland federal district court Chief Judge Solomon Oliver Jr. granted summary judgment to Wyeth, finding Buchanan’s claim that Wyeth was negligent before the FDA approved Redux was pre-empted by the FDA’s approval of the drug. Her post-approval claims of strict liability, he found, failed on their merits.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]